CoChat

The Role of Carnitine Supplementation During Valproic Acid Therapy

Raskind, Jackie Y, El-Chaar, Gladys M · 2000 · The Annals of Pharmacotherapy
Cited by 131

The DOI matches its Crossref record.

Abstract

AbstractOBJECTIVE:To review the pathophysiology and significance of valproic acid–induced carnitine deficiency; to present and evaluate the literature pertaining to carnitine supplementation in pediatric patients receiving valproic acid; and to present the consensus guidelines for carnitine supplementation during valproic acid therapy.DATA SOURCES:A MEDLINE search (1966–December 1998) restricted to English-language literature, using MeSH headings of carnitine and valproic acid, was conducted to identify clinically relevant articles. Selected articles and references focusing on the pediatric population were included for review.DATA EXTRACTION:Study design, patient population, methods, and clinical outcomes were evaluated.DATA SYNTHESIS:Valproic acid, a widely used antiepileptic agent in the pediatric population, is limited by a 1/800 incidence of fatal hepatotoxicity in children under the age of two years. Carnitine is an essential amino acid necessary in β-oxidation of fatty acids and energy production in cellular mitochondria. It has been hypothesized that valproic acid may induce a carnitine deficiency in children and cause nonspecific symptoms of deficiency, hepatotoxicity, and hyperammonemia. Relevant published case reports and trials studying this relationship are evaluated, and a consensus statement by the Pediatric Neurology Advisory Committee is reviewed.CONCLUSIONS:Despite the lack of prospective, randomized clinical trials documenting efficacy of carnitine supplementation in preventing valproic acid–induced hepatotoxicity, the few limited studies available have shown carnitine supplementation to result in subjective and objective improvements along with increases in carnitine serum concentrations in patients receiving valproic acid. The Pediatric Neurology Advisory Committee in 1996 provided more concrete indications on the role of carnitine in valproic acid therapy, such as valproic acid overdose and valproic acid–induced hepatotoxicity. Carnitine was strongly recommended for children at risk of developing a carnitine deficiency. Although carnitine has been well tolerated, future studies are needed to evaluate the efficacy of prophylactic carnitine supplementation for the prevention of hepatotoxicity. ResumenOBJETIVO:Revisar la fisiopatología e importancia de la deficiencia de carnitina inducida por ácido valproico; presentar y evaluar la literatura relativa al uso de la carnitina como suplemento en pacientes pediátricos recibiendo ácido valproico; y presentar las normas de consenso para el uso de la carnitina como suplemento durante terapia con ácido valproico.FUENTES DE INFORMACIÓN:Para identificar artículos con relevancia clínica, se realizó una búsqueda MEDLINE utilizando los términos ME S Hc arnitina y ácido valproico. La búsqueda se restringió a literatura publicada en inglés de enero 1966 a diciembre 1998. Se evaluaron artículos y referencias con énfasis en la población pediátrica.SÍNTESIS:La frequencia de hepatotoxicidad (1/800 en niños menores de dos años de edad) ha limitado el uso de ácido valproico en la población pediátrica. La carnitina es un aminoácido esencial necesario para la beta-oxidación de los ácidos grasos y para la producción de energía mitocondrial. Se ha sugerido que el ácido valproico puede inducir una deficiencia, hepatotoxicidad, e hiperamonemia. Se evaluaron informes de casos y estudios clínicos respecto a esta propuesta relación. Se informa sobre un comunicado oficial reciente del Comité Consultivo de Neurología Pediátrica.CONCLUSIONES:A pesar de la falta de estudios clínicos randomizados y prospectivos documentando su eficacia, en los estudios evaluados el uso de carnitina como suplemento ha resultado en mejoramientos sujetivos y objetivos y con incrementos en las concentraciones séricas de carnitina en pacientes recibiendo ácido valproico. En 1996, el Comité Consultivo de Neurología Pediátrica ofreció indicaciones más concretas sobre el papel de carnitina en la terapia con ácido valproico. Estas incluyeron el uso en casos de sobredosificación de ácido valproico y en casos de hepatotoxicidad inducida por ácido valproico. El Comité recomendó el uso de carnitina en niños que corren el riesgo de desarrollar una deficiencia de carnitina. Aunque parece ser bién tolerada, se requiere más estudio para evaluar la eficacia del uso de suplementos de carnitina para la prevención de hepatotoxicidad. RésuméOBJECTIF:Revoir la pathophysiologie et l'importance d'un déficit de la carnitine causée par l'acide valproique. Présenter et évaluer la littérature au sujet de la supplémentation de la carnitine chez les patients pédiatriques reçevant l'acide valproique (AV, ainsi que présenter les recommendations pour la supplémentation en carnitine durant la thérapie avec l'acide valproique.SOURCES DE DONNÉES:Afin d'identifier des articles cliniques pertinents, on a éxécuté une recherche informatisée sur MEDLINE limitée à la langue anglaise à partir de janvier 1966 jusqu'à décembre 1998, ut

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1345/1542-6270(2000)034<0630:trocsd>2.3.co;2

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 131

Metadata

Authors
Raskind, J. Y., & El-Chaar, G. M.
Venue
The Annals of Pharmacotherapy
Published
2000-05
Volume
34
Issue
5
Pages
630-638
ISSN
  • 0012-6578 (ISSN-L)
  • 1060-0280
  • 1542-6270
OpenAlex
W2122567126
Cited by
131
References
0
FWCI
2.73
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The Role of Carnitine Supplementation During Valproic Acid Therapy. https://app.cochat.ai/papers/10.1345/1542-6270(2000)034%3C0630:trocsd%3E2.3.co;2
The paper
Raskind, J. Y., & El-Chaar, G. M. (2000). The Role of Carnitine Supplementation During Valproic Acid Therapy. The Annals of Pharmacotherapy. https://doi.org/10.1345/1542-6270(2000)034%3C0630%3Atrocsd%3E2.3.co%3B2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.